Kyōwa Hakkō Kirin

from Wikipedia, the free encyclopedia
Kyōwa Hakkō Kirin

logo
legal form Kabushiki kaisha
ISIN JP3256000005
founding 1949
Seat Chiyoda , Tokyo Prefecture , JapanJapanJapan 
management Nobuo Hanai ( CEO )
Number of employees 7.152
sales 340.611 billion yen ($ 2.69 billion)
Branch Pharma, chemistry
Website kyowa-kirin.com
Stand 2013

Domperidon by Kyowa Hakko

Kyōwa Hakkō Kirin KK ( Japanese 協和 発 酵 キ リ ン 株式会社 , ~ Kabushiki kaisha , English Kyowa Hakko Kirin Co., Ltd. ) is a Japanese pharmaceutical company. It was created in 2008 through the merger of Kyōwa Hakkō Kōgyō KK ( 協和 醱 酵 工業 株式会社 ) and Kirin Pharma KK ( キ リ ン フ ァ ー マ 株式会社 ).

Kyōwa Hakkō Kirin patented hydrotalcite for medical applications ( Talcid ) and invented the fermentation process for the production of monosodium glutamate . Important drugs are e.g. B. Istradefylline , Loracarbef and Mogamulizumab , a monoclonal antibody used to treat adult T-cell leukemia . The growth regulator forchlorfenuron was also developed by Kyōwa Hakkō.

Kyōwa Hakkō includes the international subsidiaries KH Neochem and ProStrakan .

Individual evidence

  1. a b c Page no longer available , search in web archives: Annual Report 2013  ( page no longer available , search in web archivesInfo: The link was automatically marked as defective. Please check the link according to the instructions and then remove this notice. @1@ 2Template: Dead Link / v4.eir-parts.net@1@ 2Template: Dead Link / v4.eir-parts.net  
  2. About Us